Regarding COVID-19 vaccine response in CVID, a range of immunological and clinical factors have been described, including non-infectious complications and ongoing immunosuppressive therapy as well as elevated CD21low B cells, low B cells, low naïve T cells, and reduced IgA and IgM levels [7, 11, 47]. The gene discussed is CD40LG; the disease is COVID-19.